HE4 in the Diagnostic Approach of Endometrial Cancer in Patients With Postmenopausal Bleeding

  • End date
    Sep 1, 2022
  • participants needed
  • sponsor
    Nantes University Hospital
Updated on 27 September 2021


This study aims to explore the sensitivity of an innovative marker, HE4, in the diagnosis approach of endometrial cancer in case of postmenopausal bleedings.


Endometrial cancer is the most common pelvic gynecological cancer in France, ranking 5th among cancers in women in terms of incidence.

The most frequent symptom is post-menopausal bleeding and is one of the primary reasons for consultation in gynecological emergencies.

The diagnosis of endometrial cancer is made by histological analysis of endometrial tissue taken during a surgical intervention. The latter is mostly reassuring.

These interventions are often performed in mild situations and there is currently no element to be sufficiently reassuring to avoid surgery.

At present, there is no biological marker used in current practice. In the population of patients with post-menopausal bleeding requiring surgical exploration for diagnosis, the pathology results are often reassuring. These procedures could have been avoided, especially as these patients often have numerous co-morbidities and these surgeries are therefore more risky. The appearance of a new tumour marker could be useful in the management of these patients and avoid many unnecessary and risky surgeries

This study aims to explore the sensitivity of an innovative marker, HE4, in the diagnosis approach of endometrial cancer in case of postmenopausal bleedings.

Condition Menopause, ca 125, Disorder of uterus NOS, Postmenopause, Endometrial Cancer, Cancer Biomarker, Vaginal Bleeding, Uterine Cancer, Endometrial Carcinoma, ca-125, cancer antigen 125, CA-125 Antigen, uterine bleeding, Uterine Disorders, Post Menopause, Hemorrhage
Treatment Patients with Post menopausal bleeding, CA125 and HE4 assays
Clinical Study IdentifierNCT04867109
SponsorNantes University Hospital
Last Modified on27 September 2021


Yes No Not Sure

Inclusion Criteria

Patient with postmenopausal bleeding
Patient requiring hysteroscopy or hysterectomy
No objection from the patient to participate in the study

Exclusion Criteria

Non-menopausal patient
Patient under guardianship, curatorship or deprived of her freedom
Patient with proven metastases on imaging
Patient with a macroscopically suspicious cervix
Patient presenting an ovarian cyst or an associated adnexal pathology
Patient contraindicated for surgical treatment (therefore not eligible for pathological analysis)
Patient who has already been treated with hormone therapy for breast cancer
Patient who has already had surgery for this pathology, with a contributing anatomopathological result (we will therefore include patients who would not benefit from an operative hysteroscopy after performing a cornier pipelle that does not allow a positive result)
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note